For Research Use Only. Not for Human Consumption.
Recorded market$48.74Recorded exact-size market estimate: 48.74 USD for one 5 mg container (9.748600 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$56.40Member price$50.76No member savings vs. this market reference
Hexapeptide GH secretagogue for research.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 5 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$10.15/mg
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 05:11 UTC. 1 x 5 mg = 5 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Pure Bio Labs Oct 11, 2026 UTC | One 5 mg container; 69.99 USD | $14.00/mg | powder; Active purchase Price observation; no COA authentication is implied by inclusion. |
| Core Peptides Oct 11, 2026 UTC | One 5 mg container; 47.00 USD | $9.40/mg | powder; Active purchase Price observation; no COA authentication is implied by inclusion. |
| Luxe Peptides Oct 11, 2026 UTC | One 5 mg container; 40.00 USD | $8.00/mg | powder; Active purchase Price observation; no COA authentication is implied by inclusion. |
| Lab Rats Labs Oct 11, 2026 UTC | One 5 mg container; 72.00 USD | $14.40/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Element SARMs Oct 11, 2026 UTC | One 5 mg container; 44.99 USD | $9.00/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Nationwide Peptides Oct 11, 2026 UTC | One 5 mg container; 58.00 USD | $11.60/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Eros Peptides Oct 11, 2026 UTC | One 5 mg container; 31.45 USD | $6.29/mg | powder; 50 in stock Price observation; no COA authentication is implied by inclusion. |
| CellPeptides Oct 11, 2026 UTC | One 5 mg container; 39.00 USD | $7.80/mg | powder; Active purchase Price observation; no COA authentication is implied by inclusion. |
| Phiogen Oct 11, 2026 UTC | One 5 mg container; 40.00 USD | $8.00/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Vespera Peptides Oct 11, 2026 UTC | One 5 mg container; 45.00 USD | $9.00/mg | powder; Available Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Hexarelin – 5 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/hexarelin-5-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/hexarelin-5-mg/
A synthetic hexapeptide secretagogue studied for ghrelin-receptor mediated signaling in endocrine research.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Hexarelin is a synthetic peptide studied for growth-hormone-releasing activity. A small human pharmacology study showed responses through several delivery routes. It did not establish that repeated use improves strength, heals injuries or prevents cardiovascular disease.
Hexarelin is not growth hormone itself. It is also distinct from other secretagogues such as GHRP-2 and ipamorelin; pathway overlap does not establish equivalent effects.
A reported route is part of the identity of the tested intervention. Oral, nasal, subcutaneous and intravenous administration should not be collapsed into one interchangeable exposure.
The checked study included twelve healthy young volunteers and focused on the growth-hormone response. It found marked differences in biological availability between routes. That is an important qualification for claims that a result through one route validates any commercially available preparation.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Hexarelin across administration routes
Small healthy-volunteer pharmacology study Reading scope: PubMed abstract |
Hexarelin stimulated growth-hormone release, with substantially different availability across the tested routes. | A short hormone-response experiment does not establish clinical outcomes or long-term safety. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
The study shows that the compound can engage an endocrine pathway under controlled conditions. It does not establish the desirability of repeatedly producing that response in a person without a diagnosed indication.
A larger peak is not necessarily a better clinical outcome. Evaluating benefit requires measures such as function or disease outcomes, while evaluating safety requires appropriate follow-up and attention to effects outside the desired pathway.
Heart-protection or metabolic claims need their own directly relevant evidence. They cannot be established by a hormone-stimulation paper merely because other hexarelin experiments discuss related mechanisms.
A useful article should name the study population and endpoint near the claim. Describing a small volunteer experiment simply as “clinically proven” hides more information than it communicates.
Short volunteer exposure does not define repeated-use safety in older people, people with disease or people using multiple hormones. The selected study is insufficient for a blanket safety statement about those settings.
The study’s route comparisons are pharmacology findings, not a menu of personal-use methods. A milligram or microgram conversion alone cannot correct for route-dependent exposure.
The evidence does not establish a safe recurring cycle. A hormone peak or an estimated availability value is insufficient to choose one.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Check the exact peptide identity and formulation rather than accepting a generic growth-hormone-secretagogue label. If a seller uses a route-comparison study, confirm that its claim concerns the actual route and preparation in the paper.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. It measured growth-hormone release, not sport performance, strength or recovery.
The checked experiment found major route differences. An amount for one route cannot be assumed equivalent for another.
This companion to the Hexarelin research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
The study’s route comparisons are pharmacology findings, not a menu of personal-use methods. A milligram or microgram conversion alone cannot correct for route-dependent exposure.
The evidence does not establish a safe recurring cycle. A hormone peak or an estimated availability value is insufficient to choose one.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.